Predict your next investment

Private Equity
imprimis.biz

See what CB Insights has to offer

About Imprimis

The firm provides corporate finance and principal investment services. Its clients include sovereign entities, family-run businesses, multinational corporations, and high net worth individuals. Its transaction experience spans a broad range of industries, including aviation and transportation, financial institutions, consumer products, and energy.

Imprimis Headquarter Location

11A Goodwood Hill

Singapore, 258911,

Singapore

65 9127 6691

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Imprimis News

Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

Nov 27, 2018

| Source: Fundamental Markets NEW YORK, Nov. 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Abeona Therapeutics Inc. (NASDAQ: ABEO ), Great Lakes Dredge & Dock Corporation (NASDAQ: GLDD ), Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ), Alliant Energy Corporation (NYSE: LNT ), Cytokinetics, Incorporated (NASDAQ: CYTK ), and Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research. Complimentary Access: Research Reports (You may have to copy and paste the link into your browser and hit the [ENTER] key) The new research reports from Fundamental Markets, available for free download at the links above, examine Abeona Therapeutics Inc. (NASDAQ: ABEO ), Great Lakes Dredge & Dock Corporation (NASDAQ: GLDD ), Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ), Alliant Energy Corporation (NYSE: LNT ), Cytokinetics, Incorporated (NASDAQ: CYTK ), and Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below. ----------------------------------------- Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed November 23rd, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts. ----------------------------------------- Abeona Therapeutics' Recent Financial Performance For the three months ended September 30th, 2018 vs September 30th, 2017, Abeona Therapeutics reported revenue of $1.71MM vs $0.22MM (up 680.37%) and analysts estimated basic earnings per share -$0.34 vs -$0.13. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Abeona Therapeutics reported revenue of $0.84MM vs $0.89MM (down 5.85%) and analysts estimated basic earnings per share -$0.66 vs -$0.64. Analysts expect earnings to be released on March 15th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.19. The estimated EPS forecast for the next fiscal year is -$1.10 and is expected to report on March 15th, 2019. To read the full Abeona Therapeutics Inc. (ABEO) report, download it here: http://Fundamental-Markets.com/register/?so=ABEO ----------------------------------------- Great Lakes Dredge & Dock's Recent Financial Performance For the three months ended September 30th, 2018 vs September 30th, 2017, Great Lakes Dredge & Dock reported revenue of $204.32MM vs $163.32MM (up 25.11%) and analysts estimated basic earnings per share $0.19 vs -$0.05. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Great Lakes Dredge & Dock reported revenue of $702.50MM vs $767.59MM (down 8.48%) and analysts estimated basic earnings per share -$0.51 vs -$0.13. Analysts expect earnings to be released on February 19th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.12. The estimated EPS forecast for the next fiscal year is $0.45 and is expected to report on February 19th, 2019. To read the full Great Lakes Dredge & Dock Corporation (GLDD) report, download it here: http://Fundamental-Markets.com/register/?so=GLDD ----------------------------------------- Imprimis Pharmaceuticals' Recent Financial Performance For the three months ended September 30th, 2018 vs September 30th, 2017, Imprimis Pharmaceuticals reported revenue of $10.74MM vs $6.48MM (up 65.65%) and analysts estimated basic earnings per share -$0.12 vs -$0.28. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Imprimis Pharmaceuticals reported revenue of $26.77MM vs $19.94MM (up 34.26%) and analysts estimated basic earnings per share -$0.60 vs -$1.50. Analysts expect earnings to be released on March 14th, 2019. The report will be for the fiscal period ending December 31st, 2018. To read the full Imprimis Pharmaceuticals, Inc. (IMMY) report, download it here: http://Fundamental-Markets.com/register/?so=IMMY ----------------------------------------- Alliant Energy's Recent Financial Performance For the three months ended September 30th, 2018 vs September 30th, 2017, Alliant Energy reported revenue of $928.60MM vs $906.90MM (up 2.39%) and basic earnings per share $0.87 vs $0.73 (up 19.18%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Alliant Energy reported revenue of $3,382.20MM vs $3,320.00MM (up 1.87%) and analysts estimated basic earnings per share $1.99 vs $1.64 (up 21.34%). Analysts expect earnings to be released on February 28th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.33. The estimated EPS forecast for the next fiscal year is $2.24 and is expected to report on February 28th, 2019. To read the full Alliant Energy Corporation (LNT) report, download it here: http://Fundamental-Markets.com/register/?so=LNT ----------------------------------------- Cytokinetics' Recent Financial Performance For the three months ended September 30th, 2018 vs September 30th, 2017, Cytokinetics reported revenue of $10.64MM vs $6.18MM (up 72.18%) and analysts estimated basic earnings per share -$0.40 vs -$0.60. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Cytokinetics reported revenue of $13.37MM vs $106.41MM (down 87.44%) and analysts estimated basic earnings per share -$2.59 vs $0.41. Analysts expect earnings to be released on February 21st, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.75. The estimated EPS forecast for the next fiscal year is -$1.72 and is expected to report on February 21st, 2019. To read the full Cytokinetics, Incorporated (CYTK) report, download it here: http://Fundamental-Markets.com/register/?so=CYTK ----------------------------------------- Aurinia Pharmaceuticals' Recent Financial Performance For the three months ended September 30th, 2018 vs September 30th, 2017, Aurinia Pharmaceuticals reported revenue of $0.38MM vs $0.03MM (up 1,193.10%) and analysts estimated basic earnings per share -$0.21 vs -$0.16. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Aurinia Pharmaceuticals reported revenue of $0.42MM vs $0.17MM (up 142.77%) and analysts estimated basic earnings per share -$0.92 vs -$0.66. Analysts expect earnings to be released on March 21st, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.04. The estimated EPS forecast for the next fiscal year is -$0.72 and is expected to report on March 21st, 2019. To read the full Aurinia Pharmaceuticals Inc (AUPH) report, download it here: http://Fundamental-Markets.com/register/?so=AUPH ----------------------------------------- ABOUT FUNDAMENTAL MARKETS Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about. REGISTERED MEMBER STATUS Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com. LEGAL NOTICES Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website. Media Contact:

Imprimis Team

1 Team Member

Imprimis has 1 team member, including current Managing Partner, Stephen William Berger.

Name

Work History

Title

Status

Stephen William Berger

Managing Partner

Current

Name

Stephen William Berger

Work History

Title

Managing Partner

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.